Adagene and Third Arc Bio Select First Lead Candidate
San Diego, California, and Suzhou, China, September 10, 2026 Adagene Inc. and Third Arc Bio, Inc. have announced the...
Inflammation
Advertisement
Schrödinger Launches Tectora With $55 Million Series A
NEW YORK — September 9, 2026 Schrödinger, Inc. announced the formation of Tectora Therapeutics, a new biotechnology company focused...
Evommune Reports Phase 2b Setback for EVO756 in Atopic Dermatitis
PALO ALTO, Calif. and NEW YORK — September 8, 2026 Evommune, Inc. announced top-line results from its randomized, double-blind,...
BioAge Labs Begins Phase 2 Trial of Oral BGE-102
EMERYVILLE, California — September 8, 2026 BioAge Labs announced that the first participant has been dosed in the Phase...
SynAct Pharma Advances Resomelagon Toward Phase 3 in RA
Lund, Sweden, September 7, 2026 SynAct Pharma AB has reported further analyses from its Phase 2b ADVANCE clinical trial...
Advertisements
aTyr Pharma Awaits FDA Response on Efzofitimod Phase 3
SAN DIEGO, September 1, 2026 aTyr Pharma, Inc. expects to receive a response from the U.S. Food and Drug...
Rectify Advances RTY-406 as Potential Disease-Modifying Therapy for PSC
Boston, Mass. – August 27, 2026 Rectify Pharmaceuticals presented the discovery and characterization of RTY-406, an oral, once-daily investigational...
Priovant Wins FDA Approval for Lisraya in Dermatomyositis
SILVER SPRING, MARYLAND, Aug 27, 2026 Priovant Therapeutics Inc. has received U.S. Food and Drug Administration (FDA) approval for...
Raintree Expands Agentic AI for Rehab Therapy
Austin, Texas, August 20, 2026 Raintree Systems has expanded its agentic artificial intelligence (AI) platform for rehabilitation therapy, introducing...
Vascarta Begins Phase I Study of VAS-101 in SCD
Summit, New Jersey, August 20, 2026 Vascarta Inc. has announced the initiation of a Phase I clinical study of...
Advertisement
